Bullish indicating open at $55-$60, IPO prices at $37
On Tuesday, Piper Sandler, a financial services firm, adjusted its price target for Inozyme Pharma Inc . (NASDAQ:INZY) shares, bringing it down to $23 from the previous target of $30. Currently trading at $1.0 with a market capitalization of approximately $65 million, the stock remains well below analyst targets, which range from $7 to $24. Despite the reduction, Piper Sandler maintained its Overweight rating on the company’s stock.
The investment firm’s analyst, Allison M. Bratzel, expressed continued confidence in Inozyme Pharma, describing the company as a "diamond in the rough." Bratzel highlighted that although the stock has experienced a significant decline, dropping approximately 82% over the past year and currently trading near its 52-week low, Inozyme has remained on track with its operations. InvestingPro data reveals additional insights about the company’s performance, with 13 more exclusive ProTips available to subscribers. The company’s INZ-701 treatment has demonstrated promising proof of concept (POC) data and has established a clear regulatory path forward with both the FDA and EMA for the treatment of ENPP1 deficiency, a condition that could potentially generate peak revenues of at least $500 million.
Inozyme Pharma’s ENERGY-3 pivotal trial for pediatric patients has reached full enrollment, and pivotal data is expected to be released in the first quarter of 2026. Bratzel pointed out that the company’s future programs targeting ABCC6 deficiency and calciphylaxis could offer significant long-term benefits.
Piper Sandler’s analysis suggests that with the anticipated approval of INZ-701 in a largely untapped market and strategic reprioritization efforts that extend the company’s cash runway to the first quarter of 2026, the risk/reward balance for Inozyme Pharma remains positive. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 3.56 and holds more cash than debt on its balance sheet. The firm’s stance is that the current stock price presents an opportunity for investors, and they continue to recommend buying shares at the newly set price target of $23. For a complete financial health assessment and detailed valuation metrics, consider exploring InvestingPro’s comprehensive analysis tools.
In other recent news, Inozyme Pharma Inc. has reported significant developments across multiple studies involving its investigational drug, INZ-701. The company announced positive interim results from its ENERGY 1 trial, showing improvements in survival rates, heart function, and reductions in arterial calcifications in infants with ENPP1 Deficiency. The ENERGY 3 pivotal trial has completed enrollment, with topline data expected in early 2026, aiming to support the use of INZ-701 in addressing rickets. Meanwhile, analysts at H.C. Wainwright and Jefferies have expressed confidence in Inozyme’s prospects, maintaining a Buy rating with price targets of $16 and $26, respectively. Jefferies highlighted the potential of INZ-701 to become a successful treatment for rare disorders, noting its promising Phase 2 results. Raymond (NSE:RYMD) James, however, adjusted its price target from $26 to $24, citing uncertainties related to anti-drug antibodies observed in studies, while still maintaining an Outperform rating. Inozyme is also preparing for its ASPIRE pivotal trial for ABCC6 Deficiency, with plans to initiate the trial in early 2026. These recent developments reflect Inozyme’s ongoing efforts to address unmet medical needs in rare genetic disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.